Dr. Ulrike Kaufmann studied law at the Albert-Ludwigs-University in Freiburg, specialising in intellectual property law. After completing her studies, she worked as a research associate at the Institute for Commercial Law, Labour Law and Social Law, Dept. 4: Intellectual Property Law of Prof. dr. Maximilian Haedicke in Freiburg. She did her doctorate there in the field of patent law and Second Medical Use patents.

 

As part of her legal clerkship, Ulrike gained practical experience in the field of patent litigation at an international law firm, both at one of the German offices and at the London office, as part of her elective rotation.

 

Dr. Ulrike Kaufmann is a lecturer at the Verwaltungs- und Wirtschaftsakademie (VWA) in Freiburg in the field of law. She has been part of our Freiburg team since October 2019.

 

Publications:

 

2020: Authorized Generics and Biosimilars as Part of Drug Life Cycle Management, GRUR International, Volume 69, Issue 11, November 2020, Pages 1105–1112 (together with Dr. Manuel Kunst).

 

2020: Comment on EuGH-Ruling, dated October 8, 2020 – C-602/19, GRUR-Prax 2020, 570

 

2020: Aktuelle Entwicklungen rund um den FRAND-Einwand, GRUR-Prax 2020, 73-75 (together with Dr. Michael Nielen)

 

2019: Pregabalin and Fulvestrant – a comparison of German and English liability regimes of Swiss-type-claims in light of current case law; Journal of Intellectual Property Law & Practice, 06/2019, Pages 487-493 (together with Dr. Marco Stief)

 

2019: Pregabalin and Fulvestrant – a comparison of German and English liability regimes of Swiss-type-claims in light of current case law; Journal of Intellectual Property Law & Practice, 06/2019, Pages 487-493 (together with Dr. Marco Stief)

 

2019: Zwischen Pregabalin und Fulvestrant – Ein Vergleich des deutschen und englischen Haftungsregimes bei Swiss-type-claims anlässlich aktueller Rechtsprechung, GRUR 2019, 260-264 (together with Dr. Marco Stief)

 

2018: Second medical use zwischen swiss-type-claim, skinny label und cross-label-use, GRUR Newsletter 01/2018

 

2018: Der Schutzbereich von Patenten auf eine zweite medizinische Indikation im Falle eines cross-label-use, Eine rechtsvergleichende Analyse unter Begutachtung der deutschen, englischen und niederländischen Rechtsprechung (Dissertation), Carl Heymans Verlag